Investing Isn't an 'Exact Science' but the Charts Do Look Good

This post was originally published on this site

During Tuesday’s “Mad Money” program, Jim Cramer called out Exact Sciences Corp. (EXAS) , which just announced it will be acquiring the privately-held Thrive for $2.1 billion. Shares of Exact Sciences closed up 23% Tuesday.

We reviewed the charts of EXAS on Oct. 8, and wrote that, “EXAS is likely to consolidate its recent gains. I would anticipate some sideways trading in the $110-$100 area for a short period. Aggressive traders could use available weakness to go long risking a close below $95. The $187 area is our price objective.”

Let’s check out the charts again now that prices have surged close to $142.

In this daily bar chart of EXAS, below, we can see that prices traded sideways in the $110-$100 area before surging higher the other day. Traders had plenty of time to buy. Both the 50-day moving average line and the 200-day moving average line have positive slopes now. The trading volume surged and the On-Balance-Volume (OBV) line jumped to a new high telling us that buyers of EXAS have been very aggressive. The Moving Average Convergence Divergence (MACD) oscillator has crossed to the upside for a go-long signal. 

In this weekly bar chart of EXAS, below, we can see a bullish picture with a few more days in the week. Prices have surged to a new high. The 40-week moving average line now has a positive slope and the OBV line has made a new all-time high to confirm the price gains. The MACD oscillator shows a bullish alignment above the zero-line. 
In this daily Point and Figure chart of EXAS, below, we can see a potential price target in the $224 area. Not bad. 
 
Bottom line strategy: Stay long EXAS. Raise stop protection to a close below $106 from below $95. The $200 area is our first price target followed by the $224 area.